Home › Psychology Rejection › NCT03102125
Allograft Dysfunction in Heart Transplant
RecruitingPhase 4
Defining Mechanisms for Cardiac Allograft Dysfunction to Improve Allograft Longevity and Survival in Heart-Transplant Patients
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Age greater than or equal to 18 years old. * At least three months status post heart transplantation. Exclusion Criteria: * Biopsy proven acute rejection episode in the past 3 months. * Patients with symptoms or signs of acute myocardial ischemia or recent acute coronary syndrome in the past 3 months. * Uncontrolled obstructive ventilatory disease including asthma and COPD. * History of generalized tonic-clonic seizures. * Second or third degree AV nodal block. * Sinus node dysfunction. * Contraindications to MRI including cardiovascular implantable electronic devices. * Renal dysfunction with an estimated GFR less than 30 mL/min/1.73m2. * Prior adverse reaction to either regadenoson or gadolinium contrast. Prior adverse reaction to adenosine or dipyridamole will be assessed on a case-by-case basis. * Systolic blood pressure greater than 180 or less than 85 mmHg. * Diastolic blood pressure greater than 120 or less than 40 mmHg. * Resting heart rate greater than 120 or less than 45 beats per minute. - Severe claustrophobia.
About the study
The investigators will evaluate for early evidence of cardiac allograft dysfunction by cardiac MRI and single cell sequencing to determine underlying molecular and macroscopic causes.
What is being tested
- Regadenoson (drug)
Sponsor: Paul Kim · Participants: 376 · Started: Oct 1, 2019
Contact the study team
- Paul Kim, MD · Phone: 8582460638
Official record on ClinicalTrials.gov — NCT03102125
Locations in the U.S.
| California | UC San Diego, La Jolla |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.